University of California, San Francisco
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).
University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.
University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,713 total, page 5 of 35
Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care
NCT05641961
Structured Program of Exercise for Recipients of Kidney Transplantation
NCT04954690
Use of CXCL9 as a Biomarker of Acthar Efficacy
NCT02523092
TReating Incontinence for Underlying Mental and Physical Health
NCT05362292
Psoriatic Immune Response to Tildrakizumab
NCT05390515
Transcutaneous Spinal Cord Stimulation for Chronic Low Back Pain
NCT05265000
Extended Bolus for Meals in a Closed-loop System
NCT05454891
Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing
NCT05286203
Family Mental Health Family Navigator Project (FMHN)
NCT04822636
Registry of Patients Diagnosed With Lysosomal Storage Diseases
NCT05619900
Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
NCT05157113
Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer
NCT05396872
Volunteers to Investigate Best Results for Ablation and Novel Therapies for Atrial Fibrillation
NCT05504356
Dental Block for Pain Relief in ED Dental Pain Patients
NCT05351099
Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy
NCT05273307
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
NCT05057702
Peri-operative Oral Pain Control Following Buccal Graft Urethroplasty
NCT05300685
Pilot Study of Pancreatic Cancer Screening
NCT05058846
CNKSR2 Natural History Study
NCT06500260
Pulse Oximeter Accuracy in Healthy Humans During Hypoxia
NCT06142019
Understanding Motivation in Parkinson's Patients Through Neurophysiology
NCT05065151
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT05435495
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
NCT05056077
Combination Therapy for the Treatment of Diffuse Midline Gliomas
NCT05009992
Microbiome and Association With Implant Infections
NCT05020574
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
NCT05010148
Parenting Stress mHealth
NCT05032742
PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)
NCT04532047
Secondhand Tobacco Smoke and Cardiovascular Disease
NCT04715568
A Mobile Health Intervention to Reduce Sweet Beverage Consumption in Latino Children
NCT04754269
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
NCT04598009
Guselkumab Immunogenetics
NCT04645355
KIDney Injury in Times of COVID-19 (KIDCOV)
NCT04705766
Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers
NCT04722835
Improving Survivorship Care for Older Adults After Chemotherapy
NCT04405115
Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer
NCT04763980
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
NCT04485559
Biomarkers of Depression and Treatment Response
NCT04581902
Reaching for Equity in Sleep Apnea Treatment (REST) Study
NCT04209985
Medial-prefrontal Enhancement During Schizophrenia Systems Imaging
NCT04807530
SCOPE Analytic Treatment Interruption Protocol
NCT04359186
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
NCT04221893
Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
NCT04115566
Long-term Impact of Infection With Novel Coronavirus (COVID-19)
NCT04362150
Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain
NCT04144972
UCSF PANC Cyst Registry
NCT04291651
Vicryl Rapide Versus Nonabsorbable Suture
NCT04056013
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
NCT03948490
Village-Integrated Eye Worker Trial II
NCT03752840
Metformin for Pulmonary Hypertension HFpEF
NCT03629340
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 193 |
| Phase 2 | 166 |
| Phase 3 | 44 |
| Phase 4 | 152 |
Therapeutic Areas
What is open in the University of California, San Francisco pipeline
272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).
Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, San Francisco: open-pipeline peers nationwide
Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,713 trials (± recruiting share)
- Duke University · 1,725 trials · 11% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- Youngstown State University · 16% recruiting · 19 trials
- ECOG-ACRIN Cancer Research Group · 16% recruiting · 75 trials
Related
What to do with this University of California, San Francisco page
1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.
- 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets.Report a data error.